Abilify Articles
Additional indication for Otsuka’s Abilify in Japan
22 January 2012
Bristol-Myers Squibb/Otsuka’s Abilify gains expanded approval in USA
18 February 2011
First-line use of Abilify more than doubles over past year for newly-diagnosed patients with bipolar disorder
19 November 2010
UK’s NICE calls for more data on Bristol-Myers/Otsuka’s Abilify for schizophrenia; Scotland backs Novartis’Glivec
14 September 2010
Emerging oral atypical antipsychotics will garner only limited uptake in schizophrenia market
25 February 2010
Bristol-Myers Squibb decides to split off Mead Johnson nutritional unit to concentrate on biopharma
17 November 2009
Generic erosion of atypical antipsychotics will cause the bipolar disorder drug market to decline by over $1 billion through 2018
6 November 2009
Atypical antipsychotics cause significant weight gain in children and young adults, JAMA study reports
28 October 2009
Bristol-Myers sees 64% leap in 3rd quarter 2009 ongoing earnings
23 October 2009
Bristol-Myers Squibb says USPTO to review Plavix patent
20 August 2009
Patent protection for key blockbuster depression drugs will drive growth in Europe and Japan, but not USA, says DR report
18 August 2009
B-MS' 1st qtr hit by tax and legal costs
29 April 2009
Bristol-Myers Squibb an attractive value
14 April 2009
Stock Commentary - New York week to Aug 15
8 April 2009
Study results suggest B-MS/Ostuka's Abilify is safe for long-term schizophrenia combination therapy
6 April 2009
Bristol-Myers Squibb's 3rd-qtr 2008 profit triples due to big gain from $4.1B sales of ConvaTec
3 November 2008
B-MS' profit accelerates on good exchange rate
4 August 2008
B-MS' settlement for Medicaid fraud to be over $500M
21 July 2008
B-MS restructure cuts into 1st-qtr profit
5 May 2008
EC clears Abilify for bipolar disorder
14 April 2008
Otsuka settles with US DoJ for $4M
7 April 2008
Promotional spending on atypical antipsychotice analyzed
17 March 2008
FDA clears Abilify in pediatric bipolar patients
10 March 2008
CHMP OK's new indications for Abilify
3 March 2008
CHMP OK's new indications for Abilify
3 March 2008
Plavix rebound cuts B-MS' 4th-qtr 2007 loss and offsets $797M charge
11 February 2008
FDA clears Abilify as add-on to antidepressants in adults with MDD
26 November 2007
FDA grants Abilify priority review status
26 November 2007
Medarex' 3rd-qtr loss grows 12% on charges
21 November 2007
FDA clear Abilify for adolescents
12 November 2007
Patent expiries will reduce bipolar drug market $400M
1 October 2007
FDA marks Abilify sNDA for priority review
30 July 2007
Barr challenges Otsuka's Abilify patent
26 March 2007
B-MS swings to loss in 4th qtr due to Plavix
5 February 2007
Abilify delays bipolar I relapse for up to two years
18 December 2006
New hope for sufferers of manic-depression from unlikely sources
4 December 2006
Japan's generic drugs market expected to grow 8.8% from 2006 to 2008
27 November 2006
B-M S and Otsuka launch Abilify Discmelt
28 August 2006
Otsuka/B-MS Abilify gains Prix Galien
12 June 2006
B-MS's earnings hit $714M in 1st-qtr
8 May 2006
Strong results for B-MS/Otsuka's Abilify
20 March 2006
B-MS/Otsuka launch 2 new forms of Abilify
13 February 2006
4th-qtr 2005 sales drop 1% for B-MS, as patents lost
30 January 2006
UK experts back Abilify for schizophrenia
16 May 2005
B-MS 1st-qtr 2005 income down 36%
9 May 2005
FDA clears new indication for Abilify
21 March 2005
Abilify gets US OK
14 March 2005
B-MS and Otsuka introduce Abilify 5mg
17 January 2005
B-MS and Otsuka's Abilify oral solution approved by FDA
10 January 2005
More additions to Italy's Prontuario
10 January 2005
Stock Commentary - New York
1 November 2004
B-MS/Otsuka's Abilify gets OK for new use
11 October 2004
Bristol-Myers Squibb reaches $300M deal in SEC litigation; reports 42% 2nd-qtr earnings drop
9 August 2004
B-MS and Otsuka's Abilify launched in EU
28 June 2004
B-MS and Otsuka's Abilify approved in EU
14 June 2004
B-MS reports 1st-qtr earnings jump 22%
3 May 2004
20% pharma sales rise boosts B-MS profits
9 February 2004
Lilly receives product labeling letter from FDA
29 September 2003
B-MS/Otsuka's Abilify cleared for new use
15 September 2003
B-MS and Otsuka file for new use of Abilify
28 July 2003
B-MS' Reyataz for HIV
19 May 2003
Profits down 11% at B-MS in first quarter
5 May 2003
Bipolar drug market growth to 2011
3 March 2003
New filing for Abilify seeks long-term use
3 March 2003
New resistance data for B-MS' atazanavir
17 February 2003
2003 will fall below forecast, says Eli Lilly
10 February 2003
B-MS provides 2003 earnings guidance
27 January 2003
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
